Arcus Biosciences (RCUS) Q4 2025 earnings summary

Executive summary

• Casdatifan demonstrated a confirmed ORR of 45% and median PFS of 15.1 months in late-line RCC, supporting its best-in-class HIF-2α inhibitor profile, with multiple Phase 3 programs ongoing or planned.

• The company is advancing a fast-to-market strategy with the PEAK-1 Phase III study, expanding its clinical program, and planning additional Phase 3 studies in frontline RCC.

• Immunology portfolio includes five active programs, with MRGPRX2 antagonist and TNF inhibitor expected to enter the clinic by 2026–2027, targeting chronic urticaria, atopic dermatitis, and inflammatory diseases.

• Quemliclustat, the only small molecule CD73 inhibitor in clinical development, completed Phase 3 enrollment in 1L pancreatic cancer, with results expected in 2027.

• Robust oncology and immunology pipeline aims for 1–2 new molecules in the clinic annually, with at least two casdatifan data presentations expected in 2026.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1 billion at year-end 2025, up from $841 million in Q3, providing runway until at least the second half of 2028.

• Q4 2025 GAAP revenue was $33 million, with full-year 2026 guidance of $45–$55 million.

• R&D expenses for Q4 2025 were $121 million, with operating expenses expected to decrease meaningfully in 2026.

• Net loss for Q4 2025 was $106 million; net loss per share was $(0.89).

• $288 million raised in November 2025, plus $429 million from stock issuances, $50 million from a term loan, and $37 million from milestone payments in 2025.

Outlook and guidance

• PEAK-1 Phase III study is actively enrolling, with completion targeted by year-end and a fast-to-market strategy.

• Plans to initiate a second Phase III study in frontline RCC by year-end, informed by ongoing ARC-20 cohorts.

• Multiple clinical milestones expected in the next 12–24 months, including Phase 3 data readouts for PRISM-1 (pancreatic cancer) and PEAK-1 (RCC), and first-in-human studies for MRGPRX2 and TNF inhibitors.

• R&D expenses are projected to decrease meaningfully in 2026, with the magnitude dependent on the outcome of the STAR-121 futility analysis.

• At least two casdatifan data readouts are planned for 2026, including mature ORR and initial PFS data in IO-experienced and early-line settings.